Saurabh Rajpal1,2,3,4, Laith Alshawabkeh1,2,5, Nureddin Almaddah6, Caroline M Joyce2, Keri Shafer1,2, Michelle Gurvitz1,2, Sushrut S Waikar1, Finnian R Mc Causland1, Michael J Landzberg1,2, Alexander R Opotowsky1,2. 1. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 2. Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts. 3. Department of Cardiology, Nationwide Children's Hospital, Columbus, Ohio. 4. Department of Medicine, Ohio State University, Columbus. 5. Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego. 6. Department of Medicine, North Shore Medical Center, Salem, Massachusetts.
Abstract
Importance: Albuminuria is associated with adverse outcomes in diverse groups of patients, but the importance of albuminuria in the emerging population of increasingly complex adults with congenital heart disease (ACHD) remains unknown. Objective: To assess the prevalence, risk factors, and prognostic implications of albuminuria in ACHD. Design, Setting, and Participants: This prospective study assessed a cohort of ambulatory patients aged 18 years and older who were examined at an ACHD referral center and enrolled in the Boston ACHD Biobank between May 17, 2012, to August 5, 2016. Albuminuria was defined as an urine albumin-to-creatinine (ACR) ratio of 30 mg/g or more. Main Outcomes and Measures: Death or nonelective cardiovascular hospitalization, defined as overnight admission for heart failure, arrhythmia, thromboembolic events, cerebral hemorrhage, and/or disease-specific events. Results: We measured the ACR of 612 adult patients with CHD (mean [SD] age, 38.6 [13.4] years; 308 [50.3%] women). Albuminuria was present in 106 people (17.3%) and was associated with older age (patients with ACR <30 mg/g: mean [SD]: 37.5 [13.2] years; vs patients with ACR ≥30 mg/g: 43.8 [13.1] years; P < .001), presence of diabetes mellitus (ACR <30 mg/g: 13 of 506 [2.6%]; vs ≥30 mg/g: 11 of 106 [10.4%]; P < .001), lower estimated glomerular filtration rate (ACR <30 mg/g: median [interquartile range (IQR)]: 103.3 [90.0-116.4] mL/min/1.73 m2; ACR ≥30 mg/g: 99.1 [78.8-108.7] mL/min/1.73 m2; P = .002), and cyanosis (ACR <30 mg/g: 23 of 506 [5.1%]; vs ACR ≥30 mg/g: 21 of 106 [22.6%]; P < .001). After a mean (SD) follow-up time of 270 (288) days, 17 patients (2.5%) died, while 68 (11.1%) either died or experienced overnight inpatient admission. Albuminuria predicted outcome, with 30 of 106 patients with albuminuria (28.3%) affected vs 38 of 506 patients without albuminuria (7.5%; hazard ratio [HR], 3.0; 95% CI, 1.9-4.9; P < .001). Albuminuria was also associated with increased mortality (11 of 106 [10.4%]; vs 6 of 506 [1.2%] in patients with and without albuminuria, respectively; HR, 6.4; 95% CI, 2.4-17.3; P < .001). Albuminuria was associated with the outcomes only in patients with a biventricular circulation (HR, 4.5; 95% CI, 2.5-8.0) and not those with single-ventricle circulation (HR, 1.0; 95% CI, 0.4-2.8; P = 0.01 compared with biventricular circulation group). Among 133 patients (21.7%) in NYHA functional class 2, albuminuria was strongly associated with death or nonelective hospitalization. Conclusions and Relevance: Albuminuria is common and is associated with increased risk for adverse outcome in patients with ACHD with biventricular circulation. Albuminuria appears especially useful in stratifying risk in patients categorized as NYHA functional class 2.
Importance: Albuminuria is associated with adverse outcomes in diverse groups of patients, but the importance of albuminuria in the emerging population of increasingly complex adults with congenital heart disease (ACHD) remains unknown. Objective: To assess the prevalence, risk factors, and prognostic implications of albuminuria in ACHD. Design, Setting, and Participants: This prospective study assessed a cohort of ambulatory patients aged 18 years and older who were examined at an ACHD referral center and enrolled in the Boston ACHD Biobank between May 17, 2012, to August 5, 2016. Albuminuria was defined as an urine albumin-to-creatinine (ACR) ratio of 30 mg/g or more. Main Outcomes and Measures: Death or nonelective cardiovascular hospitalization, defined as overnight admission for heart failure, arrhythmia, thromboembolic events, cerebral hemorrhage, and/or disease-specific events. Results: We measured the ACR of 612 adult patients with CHD (mean [SD] age, 38.6 [13.4] years; 308 [50.3%] women). Albuminuria was present in 106 people (17.3%) and was associated with older age (patients with ACR <30 mg/g: mean [SD]: 37.5 [13.2] years; vs patients with ACR ≥30 mg/g: 43.8 [13.1] years; P < .001), presence of diabetes mellitus (ACR <30 mg/g: 13 of 506 [2.6%]; vs ≥30 mg/g: 11 of 106 [10.4%]; P < .001), lower estimated glomerular filtration rate (ACR <30 mg/g: median [interquartile range (IQR)]: 103.3 [90.0-116.4] mL/min/1.73 m2; ACR ≥30 mg/g: 99.1 [78.8-108.7] mL/min/1.73 m2; P = .002), and cyanosis (ACR <30 mg/g: 23 of 506 [5.1%]; vs ACR ≥30 mg/g: 21 of 106 [22.6%]; P < .001). After a mean (SD) follow-up time of 270 (288) days, 17 patients (2.5%) died, while 68 (11.1%) either died or experienced overnight inpatient admission. Albuminuria predicted outcome, with 30 of 106 patients with albuminuria (28.3%) affected vs 38 of 506 patients without albuminuria (7.5%; hazard ratio [HR], 3.0; 95% CI, 1.9-4.9; P < .001). Albuminuria was also associated with increased mortality (11 of 106 [10.4%]; vs 6 of 506 [1.2%] in patients with and without albuminuria, respectively; HR, 6.4; 95% CI, 2.4-17.3; P < .001). Albuminuria was associated with the outcomes only in patients with a biventricular circulation (HR, 4.5; 95% CI, 2.5-8.0) and not those with single-ventricle circulation (HR, 1.0; 95% CI, 0.4-2.8; P = 0.01 compared with biventricular circulation group). Among 133 patients (21.7%) in NYHA functional class 2, albuminuria was strongly associated with death or nonelective hospitalization. Conclusions and Relevance: Albuminuria is common and is associated with increased risk for adverse outcome in patients with ACHD with biventricular circulation. Albuminuria appears especially useful in stratifying risk in patients categorized as NYHA functional class 2.
Authors: Teun van der Bom; A Carla Zomer; Aeilko H Zwinderman; Folkert J Meijboom; Berto J Bouma; Barbara J M Mulder Journal: Nat Rev Cardiol Date: 2010-11-02 Impact factor: 32.419
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: H L Hillege; W M Janssen; A A Bak; G F Diercks; D E Grobbee; H J Crijns; W H Van Gilst; D De Zeeuw; P E De Jong Journal: J Intern Med Date: 2001-06 Impact factor: 8.989
Authors: Alexander R Opotowsky; Fernando R Baraona; Finnian R Mc Causland; Brittani Loukas; Elizabeth Landzberg; Michael J Landzberg; Venkata Sabbisetti; Sushrut S Waikar Journal: Heart Date: 2016-09-26 Impact factor: 5.994
Authors: Konstantinos Dimopoulos; Gerhard-Paul Diller; Evdokia Koltsida; Antonia Pijuan-Domenech; Sofia A Papadopoulou; Sonya V Babu-Narayan; Tushar V Salukhe; Massimo F Piepoli; Philip A Poole-Wilson; Nicky Best; Darrel P Francis; Michael A Gatzoulis Journal: Circulation Date: 2008-04-28 Impact factor: 29.690
Authors: William F Keane; Barry M Brenner; Dick de Zeeuw; Jean-Pierre Grunfeld; Janet McGill; William E Mitch; Artur B Ribeiro; Shahnaz Shahinfar; Roger L Simpson; Steven M Snapinn; Robert Toto Journal: Kidney Int Date: 2003-04 Impact factor: 10.612
Authors: Jef Van den Eynde; Thomas Salaets; Jacoba J Louw; Jean Herman; Luc Breysem; Dirk Vlasselaers; Lars Desmet; Bart Meyns; Werner Budts; Marc Gewillig; Djalila Mekahli Journal: J Am Heart Assoc Date: 2022-03-18 Impact factor: 6.106
Authors: Michelle Gurvitz; Julie E Dunn; Ami Bhatt; Wendy M Book; Jill Glidewell; Carol Hogue; Angela E Lin; George Lui; Claire McGarry; Cheryl Raskind-Hood; Alissa Van Zutphen; Ali Zaidi; Kathy Jenkins; Tiffany Riehle-Colarusso Journal: J Am Coll Cardiol Date: 2020-07-14 Impact factor: 27.203
Authors: Evi Ritmeester; Veerle A Veger; Jelle P G van der Ven; Gabrielle M J W van Tussenbroek; Carine I van Capelle; Floris E A Udink Ten Cate; Willem A Helbing Journal: Front Cardiovasc Med Date: 2022-03-22